<DOC>
	<DOC>NCT01514448</DOC>
	<brief_summary>Patients with metastatic renal cell carcinoma (mRCC) who have failed first-line therapy with sunitinib or pazopanib will be treated with everolimus. Efficacy and safety of everolimus will be evaluated in theses patients.</brief_summary>
	<brief_title>Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma. Progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mRCC. Patients scheduled for treatment with everolimus. Patients with at least one measurable lesion at baseline. Patients who have received &gt;1 prior systemic treatment for their metastatic RCC. Prior systemic treatment in an adjuvant setting is allowed. Patients who have previously received systemic mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus). Patients who are using other investigational agents or who had received investigational drugs â‰¤ 2 weeks prior to study treatment start. Patients unwilling or unable to comply with the protocol. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>mRCC</keyword>
	<keyword>metastic renal cell carcinoma</keyword>
	<keyword>everolimus</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pazopanib</keyword>
</DOC>